Residency · Los Angeles, CA
Sponsored by UCLA David Geffen School of Medicine/UCLA Medical Center
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 922 citations · Jane Yanagawa
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 1,255 citations · Jane Yanagawa
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 813 citations · Jane Yanagawa
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 469 citations · Jane Yanagawa
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer cell · 2021 · 843 citations · Jack Roth
Transplantation Outcomes with Donor Hearts after Circulatory Death.
The New England journal of medicine · 2023 · 293 citations · Fardad Esmailian
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nature medicine · 2021 · 558 citations · Jack Roth
Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance.
Cancer cell · 2025 · 86 citations · Jack Roth